PIVKA-II, a biomarker for early diagnosis of hepatocellular carcinoma (HCC)


Oncology is one of the main specializations of the hospital. The Hepatology Unit at the Hôpital Cochin is closely involved in the follow-up of patients with viral or alcoholic hepatitis who are at risk of developing hepatocellular carcinoma (HCC) and makes extensive use of alphafoetoprotein (AFP) assays to diagnose this pathology. In this context, Fujirebio France has introduced the laboratory to the measurement of PIVKA-II (Protein Induced by Vitamin K Absence or Antagonist II), an inactive precursor of prothrombin.

Read more »

You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below:

Welcome to Fujirebio

It looks as if you are visiting from the United States. The content of this website is not destined for United States visitors.

If you continue your visit you confirm that you understand that not all of the products you will see listed are FDA cleared. FDA cleared products may not be cleared for all indications mentioned on this site. Product claims may differ from country to country based on regulations and approvals.

Please contact your country representative for further details.